Cytokinetics Inc. (NASDAQ:CYTK) shares traded down 0.8% during mid-day trading on Monday . The company traded as low as $12.06 and last traded at $12.13, with a volume of 201,925 shares trading hands. The stock had previously closed at $12.23.

A number of research analysts have issued reports on the company. FBR & Co reiterated a “buy” rating on shares of Cytokinetics in a research report on Monday, May 2nd. Zacks Investment Research cut Cytokinetics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Piper Jaffray Cos. restated an “overweight” rating and set a $24.00 price target on shares of Cytokinetics in a report on Wednesday, May 25th. JMP Securities restated a “buy” rating and set a $17.00 price target on shares of Cytokinetics in a report on Tuesday, August 2nd. Finally, Roth Capital restated a “buy” rating and set a $22.00 price target on shares of Cytokinetics in a report on Thursday, August 18th. Eight equities research analysts have rated the stock with a buy rating, Cytokinetics has a consensus rating of “Buy” and a consensus price target of $18.13.

The company’s market cap is $483.98 million. The company’s 50 day moving average is $11.16 and its 200 day moving average is $8.65.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.02. On average, equities analysts predict that Cytokinetics Inc. will post ($1.30) EPS for the current fiscal year.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.